The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages

Leukemia and Lymphoma

Volumn 38, Issue 1-2, 2000, Pages 153-163

  Alemany, Mònica ^a   Levin, Jack ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arsenic trioxide; As2O3; Essential Thrombocythemia; Megakaryocytic cell lines

Indexed keywords

ARSENIC TRIOXIDE; CASPASE; GLUTATHIONE; PROTEIN BCL 2;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTHEMIA;

EID: 0034006921     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009060329     Document Type: Article

References (37)

1. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360.
2. Soignet SL, Maslak P, Wang Z-G, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove JL, Scheinberg DA, Pandolfi PP, Warrell RP Jr. (1998). Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348.
3. Mu ZM, Chin KV, Liu J W, Lozano G, Chang KS (1994). PML, a growth suppressor disrupted in acute promyelocytic leukemia. MoI Cell Biol 14: 6858-6867.
4. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 88: 1052-1061.
5. 3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345-3353.
6. Shao W, Fanelli M, Ferrara FF Riccioni R, Rosenauer A, Davison K, Lamph WW. Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr (1998). Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90: 124-133.
7. Wang Z-G, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP Jr, Pandolfi PP (1998). Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood 92: 1497-1504.
8. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, Fermand JP (1999). Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 59: 1041-1048.
9. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, Chen GQ (1999). Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 91: 772-778.
10. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A, Ohno R (1998). The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 12: 1383-1391.
11. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K (1998). Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol 102: 1055-1060.
12. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O, de Thé H (1999). Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type l-transformed cells. Blood 93: 278-283.
13. Akao Y, Nakagawa Y, Akiyama K (1999). Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation ot caspase 3 in vitro. FEBS Lett 455: 59-62.
14. Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP, Han ZC (1999). Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 27: 845-852.
15. Wyllie AH (1997). Apoptosis and carcinogenesis. Eur J Cell Biol 73: 189-197.
16. Rudel T, Bokoch GM (1997). Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation ot PAK2. Science 257: 1571-1574.
17. Quignon F, De Bels F, Koken M, Feuteun J, Ameisen JC, de Thé H (1998). PML induces a caspase-independent cell death process. Nat Genet 20: 2559-2565.
18. König A. Wrazel L. Warrell RP Jr, Rivi R, Pandolti PP, Jakubowski A, Gabrilove JL (1997). Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 90: 562-570.
19. Dai J, Weinberg RS, Waxman S, Jing Y (1999). Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93: 268-277.
20. Chen YC, Lin-Shiau SY, Lin JK (1998). Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 177: 324-333.
21. Muller S, Malunis MJ, Dejean A (1998). Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 17: 61-70.
22. Zhu J, Koken MH. M, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de Thé H (1947). Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94: 3978-3983.
23. Melnick A. Licht JD (1999). Deconstructing a disease: RARα its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167-3215.
24. Chen Z, Wang ZY, Chen SJ (1997). Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther 76: 141-149.
25. Daniel MT, Koken M, Romagné O, Barbey S, Bazarbachi A, Stadler M, Guillemin MC, Degos L, Chomienne C, de Thé H (1993). PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82: 1858-1867.
26. Lam YW, Ammerlaan W, Kroese F, Opslelten D (1995). Cell type-and differentiation stage-dependent expression of PML domains in rat, detected by monoclonal antibody HIS55. Exp Cell Res 221: 344-356.
27. Nason-Buchenal K, Gandini D, Botto M, Allopenna J, Seale JRC, Cross NCP, Goldman JM, Dmitrovsky E, Pandolfi PP (1996). Interferon augments PML and PML/RARα expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line. Blood 88: 3926-3936.
28. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de Thé H (1994). The t(15:17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 13: 1073-1083.
29. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M (1996). The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15: 6269-6279.
30. Chen W, Martindale JL, Holbrook NJ, Liu Y (1998). Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and She. Mol Cell Biol 18: 5178-5188.
31. Jing Y, Dai J, Chalmers-Redmen RME, Tatton WG, Waxman S (1999). Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94: 2102-2111.
32. Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, Ruthardt M (1999). PIC-I/SUMO-l-modified PML-retinoic acid receptor α mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 19: 5170-5178.
33. Li YM, Broome, JD (1999). Arsenic targets tubulins to induce apotosis in myeloid leukemia cells. Cancer Res 59: 776-780.
34. Sato T, Ota S, Kakuda H, Miura N, Niimi H, Ito M, Asai T, Tsuruo T, Fuse A (1995). Expression of multidrug resistant gene (mdr-l/P-glycoprotein) in a megakaryoblastic leukaemia cell line CMK, and its enhancement during megakaryocytic differentiation. Leuk Lymphoma 18: 515-520.
35. San Miguel JF, Gonzalez M, Canizo MC, Ojeda E, Orfao A, Caballero MD, Moro MJ, Fisac P, Lopez Borrasca A (1988). Leukemias with megakaryoblastic involvement: clinical, hematologic, and immunologic characteristics. Blood 72: 402-407.
36. Cripe LD, Hromas R (1998). Malignant disorders of megakaryocytes. Semin Hematol 35: 200-209.
37. Murphy S (1998). Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 36: 9-13.